Drugs and FDA
Lutikizumab improved patient response in AbbVie’s Phase 3 trial, and an FDA filing is likely next year, according to Endpoints News.
The original reports on this story are listed below.
Cancer
In a phase 3 melanoma trial, intismeran autogene plus Keytruda cut relative recurrence-or-death risk by 42% versus Keytruda alone, BioPharma Dive reported.
Insurance
KFF found the average family premium reached $28,303 in 2026, while workers paid an average $7,471 toward it, up 9%.
Infectious disease
The patient was severely immunocompromised and died in early October. Investigations into the infection and its possible role in the death are ongoing.
This Week in Medicine
The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.
Free. No spam. Unsubscribe anytime.